Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06174623
Other study ID # MH-ADHF-001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 2024
Est. completion date December 2024

Study information

Verified date June 2024
Source Puzzle Medical Devices Inc.
Contact Gabriel Georges
Phone 514-758-8971
Email gabriel.georges@puzzlemed.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of the safety and efficacy of the ModulHeart System in patients hospitalized with acute decompensated heart failure (ADHF) and diuretic resistance


Description:

The study is a prospective, single-arm, non-randomized feasibility study to evaluate the safety and performance of the ModulHeart System in patients hospitalized with ADHF and diuretic resistance. The ModulHeart system consists of the ModulHeart Delivery System, the ModulHeart Pumps, the ModulHeart Controller, and the ModulHeart Retrieval System.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 5
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: 1. Admitted to the hospital with a primary diagnosis of ADHF 2. Clinical signs and/or symptoms of congestion defined as at least one of the following: dyspnea at rest or with minimal exertion, orthopnea, lower extremity edema (=2+), elevated jugular venous pressure, pulmonary rales, pulmonary vascular congestion on chest x-ray, pleural effusion or ascites 3. Projected need by the treating clinician for continued treatment with IV diuretic agents for more than 48 hours with the goal of significant fluid removal (more than 1L net fluid loss/24h) 4. Appropriate intravenous loop diuretic therapy at the time of enrollment, defined as at least the higher of: 1. Furosemide 40mg IV bid or equivalent 2. IV furosemide or equivalent IV loop diuretic equivalent to =2x the total oral daily loop diuretic dose at home in 2 divided doses 5. Diuretic resistance defined as at least ONE of the following: 1. Urine output of less than 1.5L over 12h following the last diuretic dose, OR 2. Net fluid loss of less than 1L over the last 24 hours, OR 3. Spot urinary sodium concentration of less than 70 mmol/L 2h following the last diuretic dose or cumulative 6-hour natriuresis of less than 100 mmol following the last diuretic dose, OR 4. Clinically unsatisfactory resolution of congestion 6. Age = 21 years old 7. Signed informed consent Exclusion Criteria: 1. ADHF related to acute secondary disease (i.e., infection or acute coronary syndrome) 2. Treatment with high dose inotropes (milrinone =0.375 mcg/kg/min, dobutamine =5mcg/kg/min or dopamine =5mcg/kg/min) and/or treatment with vasopressors to maintain a systolic arterial blood pressure =90 mmHg or mean arterial blood pressure =60 mmHg 3. Current or previous support with a durable left ventricular assist device (LVAD) at any time or use of an extracorporeal membrane oxygenation (ECMO), percutaneous ventricular assist devices, intra-aortic balloon pump or patient on home inotropes currently or within the last 30 days 4. Recent myocardial infarction, percutaneous coronary intervention or surgical revascularization (within the last 30 days) or awaiting planned coronary intervention or surgery 5. Fixed pulmonary vascular resistance of more than 5 Wood units, estimated PASP of more than 80 mmHg as measured on echocardiogram or echocardiographic evidence of primarily right heart failure 6. Prior heart transplant, heart failure due to rejection of a previous heart transplant, or planned heart transplantation 7. Reanimated cardiac arrest in the last 30 days 8. Suspected or known amyloid disease or other restrictive cardiomyopathy 9. Severe bleeding risk precluding anticoagulation: 1. Previous intracranial bleed unless there is documentation in the medical record (from a physician that is not part of the study) that the patient can safely use anticoagulation for 3 days 2. Gastrointestinal (GI) bleeding within 1 month requiring hospitalization and/or transfusion 3. Recent major surgery within 1 month if the surgical wound is judged to be associated with an increased risk of bleeding 4. Platelet count of less than 50,000 cells/mm3 5. Uncorrectable bleeding diathesis or coagulopathy 10. Contraindicated anatomy: 1. Descending aortic anatomy that would prevent safe placement of the device (less than 18 mm or more than 28mm thoracoabdominal aorta diameter at deployment location) 2. Abnormalities of the aorta or subclavian or axillary arteries that would prevent safe device placement, including aneurysms, significant tortuosity, or calcifications 3. Axillary artery anatomy that would preclude safe placement of a 10F sheath including severe obstructive calcification or severe tortuosity 4. Iliofemoral artery anatomy that would preclude safe placement of a 16F introducer sheath including severe obstructive calcification or severe tortuosity 5. Known connective tissue disorder (e.g. Marfan Syndrome) or other aortopathy at risk of vascular injury 6. Prior endovascular surgery or percutaneous intervention involving the thoracoabdominal aorta or a subclavian/axillary artery or history of aortic dissection 11. Severe aortic stenosis 12. Known or suspected contrast induced nephropathy 13. Absolute contraindications or allergy to iodinated contrast that cannot be adequately treated with pre-medication 14. Absolute contraindications or allergy to unfractionated heparin (e.g., heparin-induced thrombocytopenia) or device materials (e.g. nickel, titanium) that cannot be adequately treated with pre-medication 15. Known hematologic diseases such as leukemia, any coagulopathy or hypercoagulable state, sickle cell anemia or thalassemia 16. Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure: 1. Liver disease (cirrhosis of the liver [Child-Pugh class B or C]) or shock liver 2. History of severe chronic obstructive pulmonary disease (COPD) defined by FEV1/FVC less than 0.7, and FEV1 less than 50% predicted 3. Prior kidney transplant, isolated single kidney, stage V Chronic Kidney Disease (eGFR =15) at admission OR use of dialysis, continuous renal replacement therapy (CRRT) or aquapheresis (ultrafiltration) in last 90 days 17. Cardiac imaging evidence of intracardiac mass, thrombus, or vegetation 18. Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 90 days prior to the index procedure 19. Active infection not controlled with antibiotic therapy 20. Suspected or known pregnancy. Women of child-bearing age should have a negative pregnancy test. 21. Body mass index (BMI) over 40 kg/m2 22. Unable or unwilling to undergo screening, device implant and retrieval procedures, and 30-day follow-up 23. Currently participating in an investigational drug or another device study that may influence the data collected for this study. Observational studies are not considered an exclusion 24. Subject has other medical, social or psychological problems that, in the opinion of the Investigator, compromises the subject ability to give written informed consent and/or to comply with study procedures 25. Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments

Study Design


Related Conditions & MeSH terms


Intervention

Device:
ModulHeart Support
The ModulHeart device will be implanted in the descending abdominal aorta.

Locations

Country Name City State
Australia The Victorian Heart Hospital Clayton Victoria
Georgia Emergency Cardiology Center by Academician G. Chapidze Tbilisi
Georgia Israeli-Georgian Medical Research Clinic Helsicore Tbilisi
Georgia Tbilisi Heart and Vacular Clinic Tbilisi
Georgia Tbilisi Heart Center Tbilisi

Sponsors (1)

Lead Sponsor Collaborator
Puzzle Medical Devices Inc.

Countries where clinical trial is conducted

Australia,  Georgia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Device safety defined as freedom from serious in-hospital procedure or device-related adverse event (AE) Baseline to 30-day Follow-Up
Primary Technical success defined as successful device deployment, ability to deliver the treatment and remove the device Baseline to 30-day Follow-Up
Primary Assisted decongestion success defined as increase in the average hourly rate of urine output during the first 24 hours of ModulHeart-assisted decongestive therapy compared to the last 24 hours of diuretic therapy prior to pump implant Baseline to 1 day of ModulHeart-assisted decongestive therapy
Secondary Change in urine output Baseline to end of ModulHeart therapy (up to 3 days)
Secondary Change in net fluid loss Baseline to end of ModulHeart therapy (up to 3 days)
Secondary Change in natriuresis Baseline to end of ModulHeart therapy (up to 3 days)
Secondary Change in creatinine clearance Baseline to end of ModulHeart therapy (up to 3 days)
Secondary Change in N-terminal pro-B type natriuretic peptide (NT-pro BNP) Baseline to end of ModulHeart therapy (up to 3 days)
Secondary Change in body weight Baseline to end of ModulHeart therapy (up to 3 days)
Secondary Change in thermodilution cardiac output Baseline to end of ModulHeart therapy (up to 3 days)
Secondary Change in right atrial pressure Baseline to end of ModulHeart therapy (up to 3 days)
Secondary Change in mean pulmonary artery pressure Baseline to end of ModulHeart therapy (up to 3 days)
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy